To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC41841 | Brain Natriuretic Peptide (1-32), rat acetate |
Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).
More description
|
|
| DC41840 | LL-37 scrambled peptide acetate |
LL-37 scrambled peptide acetate is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide acetate can be used as a negative control of LL-37 peptide studies.
More description
|
|
| DC41839 | Antioxidant peptide A TFA |
Antioxidant peptide A TFA is a short peptide, which contains alternative aromatic or sulfur-containing amino acid. The side chains of Antioxidant peptide A are believed to contribute to strong radical scavenging activities of peptides in the cancer cell.
More description
|
|
| DC41838 | Bactenecin TFA |
Bactenecin TFA (Bactenecin, bovine TFA) is a potent 12-aa looped antimicrobial peptide isolated from bovine neutrophils. Bactenecin TFA inhibits the growth of bacteria and yeast, and kills the fungus Trichophyton rubrum. Bactenecin TFA increass membrane permeability, inhibits the growth and biofilm formation of B. pseudomallei.
More description
|
|
| DC41837 | β-Amyloid (22-35) (TFA) |
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).
More description
|
|
| DC41836 | Acetyl-pepstatin |
Acetyl-pepstatin is a high affinity aspartic protease inhibitor. Acetyl-pepstatin inhibits HIV-1 protease (Ki=20 nM at pH 4.7) and HIV-2 protease (Ki= 5 nM at pH 4.7). Antiviral.
More description
|
|
| DC41835 | BA 1 TFA |
BA 1 TFA is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). BA 1 TFA enhances glucose transport in obese and diabetic primary myocytes. BA 1 TFA also stimulates NCI-H1299 lung cancer cell proliferation in vitro.
More description
|
|
| DC41834 | BA 1 |
BA 1 is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). BA 1 enhances glucose transport in obese and diabetic primary myocytes. BA 1 also stimulates NCI-H1299 lung cancer cell proliferation in vitro.
More description
|
|
| DC41833 | Spadin TFA |
Spadin TFA, a natural peptide derived from a propeptide released in blood, is able to block the TREK-1 (KCNK2 or K2P2.1) channel activity. Spadin TFA binds specifically to TREK-1 with an affinity of 10 nM. Spadin TFA is an efficient antidepressant in mice.
More description
|
|
| DC41832 | Spadin |
Spadin, a natural peptide derived from a propeptide released in blood, is able to block the TREK-1 (KCNK2 or K2P2.1) channel activity. Spadin binds specifically to TREK-1 with an affinity of 10 nM. Spadin is an efficient antidepressant in mice.
More description
|
|
| DC41831 | TAT-cyclo-CLLFVY |
TAT-cyclo-CLLFVY is a selective HIF-1 dimerization inhibitor. TAT-cyclo-CLLFVY blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50=1.3 μM). TAT-cyclo-CLLFVY inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. TAT-cyclo-CLLFVY also reduces tubularization of hypoxic HUVECs.
More description
|
|
| DC41830 | AP 811 |
AP 811 is a selective atrial natriuretic peptide clearance receptor (APN-CR, NPR3) antagonist (Ki=0.48 nM). AP 811 displays >20,000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation.
More description
|
|
| DC41829 | DPC-AJ1951 TFA |
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR) , and characterized its activity in ex vivo and in vivo assays of bone resorption.
More description
|
|
| DC41828 | GRK2i |
GRK2i is a GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. GRK2i corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.
More description
|
|
| DC41827 | AC 187 TFA |
AC 187 TFA is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 TFA blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 TFA increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.
More description
|
|
| DC41826 | AC 187 |
AC 187 is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.
More description
|
|
| DC41825 | ZIP(Scrambled) TFA |
ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP).
More description
|
|
| DC41824 | ZIP(Scrambled) |
ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP).
More description
|
|
| DC41823 | d[Cha4]-AVP TFA |
d[Cha4]-AVP TFA is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). d[Cha4]-AVP TFA stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.
More description
|
|
| DC41822 | d[Cha4]-AVP |
d[Cha4]-AVP is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). d[Cha4]-AVP stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.
More description
|
|
| DC41821 | Neuropeptide S (human) |
Neuropeptide S human is a potent endogenous neuropeptide S receptor agonist (EC50= 9.4 nM). Neuropeptide S human increases locomotor activity and wakefulness in mice. Neuropeptide S human also reduces anxiety-like behavior in mice.
More description
|
|
| DC41820 | Rac1 Inhibitor F56, control peptide TFA |
Rac1 Inhibitor F56, control peptide TFA is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide TFA does not affect GEF-Rac1 interaction.
More description
|
|
| DC41819 | Rac1 Inhibitor F56, control peptide |
Rac1 Inhibitor F56, control peptide is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide does not affect GEF-Rac1 interaction.
More description
|
|
| DC41818 | Rac1 Inhibitor W56 TFA |
Rac1 Inhibitor W56 TFA is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 TFA selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.
More description
|
|
| DC41817 | Rac1 Inhibitor W56 |
Rac1 Inhibitor W56 is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.
More description
|
|
| DC41816 | Amyloid β-Peptide(1-43)(human) TFA |
Amyloid β-Peptide(1-43) human TFA, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.
More description
|
|
| DC41815 | Amyloid β-Peptide(1-43)(human) |
Amyloid β-Peptide(1-43) human, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.
More description
|
|
| DC41814 | Caffeic acid-pYEEIE TFA |
Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
More description
|
|
| DC41813 | Caffeic acid-pYEEIE |
Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
More description
|
|
| DC41812 | G-Protein antagonist peptide TFA |
G-Protein antagonist peptide TFA is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide TFA competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors.
More description
|
|